| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
| The first 150 words of the full text of this article appear below. |
The leukotriene receptor antagonists (LTRAs) constitute the first completely new class of drugs for use in asthma for 25 years. Their development was based on the recognition that cysteinyl leukotrienes exhibit biological activities that mimic some of the clinical features of asthma and are detectable in increased amounts in asthmatic patients, particularly during exacerbations of asthma. Potent and specific LTRAs have been developed and marketed for use in the treatment of asthma in the UK. Their use by clinicians in the UK is usually as "add-on" therapy in chronic asthma at steps 3, 4, or 5 of the BTS asthma guidelines.
In this issue of Thorax Dockhorn
et al compare the effect of intravenous and
oral administration of the LTRA montelukast on airway
function.1 Their results confirm those of previous studies that have shown improved pulmonary function after administration of an
LTRA in asthmatic patients, and they also found that intravenous montelukast had a
This article has been cited by other articles:
|
|
 |
|
  R. A. Silverman, R. M. Nowak, P. E. Korenblat, E. Skobeloff, Y. Chen, C. M. Bonuccelli, C. J. Miller, and S. G. Simonson Zafirlukast Treatment for Acute Asthma: Evaluation in a Randomized, Double-Blind, Multicenter Trial Chest, November 1, 2004; 126(5): 1480 - 1489. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P Phipps and C S Garrard The pulmonary physician in critical care * 12: Acute severe asthma in the intensive care unit Thorax, January 1, 2003; 58(1): 81 - 88. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. ECHAZARRETA, B. DAHLEN, G. GARCIA, C. AGUSTI, J. A. BARBERA, J. ROCA, S.-E. DAHLEN, and R. RODRIGUEZ-ROISIN Pulmonary Gas Exchange and Sputum Cellular Responses to Inhaled Leukotriene D4 in Asthma Am. J. Respir. Crit. Care Med., July 15, 2001; 164(2): 202 - 206. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
